诺诚健华：新型BCL2抑制剂Mesutoclax最新临床数据亮相第67届美国血液学会（ASH）年会

Core Insights - The company announced the presentation of three studies on its novel BCL2 inhibitor Mesutoclax (ICP-248) at the 67th American Society of Hematology (ASH) annual meeting [1] - Mesutoclax demonstrated excellent efficacy and safety in treating relapsed/refractory mantle cell lymphoma (MCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and acute myeloid leukemia (AML) [1] - The study on Mesutoclax for relapsed/refractory MCL was selected for oral presentation, while the studies for CLL/SLL and AML were selected for poster display [1]